Skip to main content

Wuxi Biologics Cay New(WXIBF)
OTC US

Today's Change
Delayed Last Update
Day Low4.7000
Day High4.7000
Open:4.7000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Tipranks
Citi Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
Tipranks
Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Alkermes (ALKS)
Tipranks
Guotai Haitong Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
Tipranks
CLSA Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
Tipranks
Daiwa Remains a Buy on Wuxi Biologics (Cayman) (WXIBF)
Tipranks
Wuxi Biologics (Cayman) (WXIBF) Gets a Buy from UOB Kay Hian
Tipranks
Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from CICC
Tipranks
Wuxi Biologics (Cayman) (WXIBF) Gets a Buy from UBS
Tipranks
Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from Bank of China
Tipranks
Wuxi Biologics (Cayman) (WXIBF) Receives a Hold from Bank of America Securities
Tipranks
Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme
Tipranks
WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors
Tipranks
Wuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands
Tipranks
Zhongtai Securities Reaffirms Their Buy Rating on Wuxi Biologics (Cayman) (WXIBF)
Tipranks
China Renaissance Remains a Buy on Wuxi Biologics (Cayman) (WXIBF)
Tipranks
WuXi Biologics Sets March 24 Board Meeting to Approve 2025 Annual Results
Tipranks
WuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains
Tipranks
CICC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
Tipranks
WuXi Biologics’ Substantial Shareholder to Cut Stake via HK$38.52 Block Trade
Tipranks
Citigroup-Backed HK$4.00 Cash Offer Launched for Wuxi Biologics Shares at 99% Premium
Tipranks
WuXi Biologics Highlights Strong 2025 Pipeline and Growth Ahead of J.P. Morgan Healthcare Conference
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Wuxi Biologics (Cayman) (OtherWXIBF) and Avalo Therapeutics (AVTX)
Tipranks
Goldman Sachs Keeps Their Hold Rating on Wuxi Biologics (Cayman) (WXIBF)
Tipranks
HSBC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
Tipranks
UBS Reaffirms Their Buy Rating on Wuxi Biologics (Cayman) (WXIBF)
Tipranks
Wuxi Biologics Proposes Revised Cap and Renewal of Service Agreement Amid Growing Demand
Tipranks
DBS Sticks to Their Hold Rating for Wuxi Biologics (Cayman) (WXIBF)
Tipranks
J.P. Morgan Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
Tipranks
Macquarie Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
Tipranks
Goldman Sachs Keeps Their Hold Rating on Wuxi Biologics (Cayman) (WXIBF)
Tipranks
Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Cingulate Inc (CING)

Profile

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.